CPT 82024: Adrenocorticotropic Hormone (ACTH) Quantitative Assay
Commercial payers pay $81 on average nationally for this procedure.
CPT code 82024 is a quantitative laboratory assay for adrenocorticotropic hormone (also called corticotropin) used to evaluate adrenal function and distinguish primary from secondary adrenal insufficiency; this service is a clinical laboratory endocrine diagnostic test typically performed in a hospital or outpatient laboratory setting and reported as a standalone quantitative hormone assay.
For related coverage guidance, see recent payer policy updates: Salivary Hormone Testing, Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing, Bone Turnover Markers Testing.
Customize your policy alerts
Sign up for cpt 82024 policy alerts
Get alerted when payer policies referencing 82024 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for CPT 82024 show BUCA (average commercial) centered at $81.20, while individual commercial payers vary: Aetna has a relatively low mean at $33.30, Cigna and UnitedHealth Group sit near the low-to-mid $30s–$40s with means of $42.70 and $39.00 respectively, and Blue Cross Blue Shield displays the highest dispersion and mean at $113.40. Blue Cross Blue Shield’s maximum outlier of $460.20 drives a wider distribution compared with others, creating notable upward pressure on the upper tail of the market.
Assessing dispersion via interquartile range (P75 minus P25) highlights differences in rate consistency: Blue Cross Blue Shield has the widest IQR at $58.70 ($137.50 - $80.80), indicating the least tight pricing band among payers. UnitedHealth Group and Cigna show moderate dispersion with IQRs of $24.70 ($46.90 - $23.20) and $33.30 ($56.00 - $23.70) respectively, while Aetna’s IQR is the tightest at $12.00 ($37.00 - $25.00). BUCA’s quartiles ($56.40, $68.80, $98.59) imply a mid-to-upper commercial range centered on the $81.20 mean.